Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBT (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of EBT data on record, last reported at -$203.3 million in Q4 2025.

  • For Q4 2025, EBT fell 463.57% year-over-year to -$203.3 million; the TTM value through Dec 2025 reached -$120.5 million, up 38.74%, while the annual FY2025 figure was -$120.5 million, 38.74% up from the prior year.
  • EBT reached -$203.3 million in Q4 2025 per APLS's latest filing, down from $216.3 million in the prior quarter.
  • Across five years, EBT topped out at $401.2 million in Q4 2022 and bottomed at -$219.2 million in Q2 2021.
  • Average EBT over 5 years is -$59.6 million, with a median of -$106.9 million recorded in 2023.
  • The widest YoY moves for EBT: up 480.48% in 2025, down 463.57% in 2025.
  • A 5-year view of EBT shows it stood at $283.7 million in 2021, then skyrocketed by 41.4% to $401.2 million in 2022, then tumbled by 109.63% to -$38.7 million in 2023, then rose by 6.7% to -$36.1 million in 2024, then plummeted by 463.57% to -$203.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$203.3 million in Q4 2025, $216.3 million in Q3 2025, and -$41.7 million in Q2 2025.